Table 1 Overview of reported cases of bilateral herpes zoster (BHZ)
From: Bilateral asymmetrical herpes-zoster with Ramsay hunt syndrome in an immunocompetent adult
NO. | Age (years) | Sex | Dermatomes | Symmetry | Underlying disease | Treatment | Reference (see supplementary materials for details) |
|---|---|---|---|---|---|---|---|
1 | 61 | M | R: T2–3 L: C5-T1 | Asymmetry | / | VCV oral 1 g/q8h 7 days | 1 |
2 | 24 | F | R: L1–2 L: maxillary dermatome | Asymmetry | / | ACV oral 800 mg × 5/d 10 days | 2 |
3 | 7 | M | R: C4 L: T3–4, L2 | Asymmetry | / | ACV oral 800 mg × 5/d 7 days | 3 |
4 | 16 | M | R: trigeminal nerve dermatome L: T4–7 | Asymmetry | / | ACV oral 500 mg × 3/d 7 days | 4 |
5 | 45 | M | R: T9 L: trigeminal nerve dermatome | Asymmetry | / | ACV IV 10 mg/kg × 3/d | 5 |
6 | 26 | M | R: T8 L: T9 | Asymmetry | / | ACV 800 mg × 5/d 7 days | 6 |
7 | 73 | F | R: L1–2 L: T9–10 | Asymmetry | / | Isoprinosine 1.000 mg × 4/d | 7 |
8 | 60 | M | R: trigeminal nerve dermatome, forearm L: back | Asymmetry | / | Prednisolone oral 40 mg/d topical ACV and steroids | 8 |
9 | 40 | F | R: neck and ear L: neck and shoulder | Asymmetry | / | Quinine, iron and sulphateof magnesia oral | 9 |
10 | 28 | M | R: T8–9 L: T12, L1–2 | Asymmetry | / | ACV oral 800 mg × 5/d 7 days | 10 |
11 | 14 | M | R: forehead L: L1 | Asymmetry | / | ACV IV 1500 mg/m2/dClindamycin IV | 11 |
12 | 21 | M | Trigeminal nerve dermatome | Symmetry | / | ? | 12 |
13 | 3 | M | Face, nose, chin and ear | Symmetry | / | Triple sulfa and penicillin | 12 |
14 | 41 | F | Neck | Symmetry | / | No treatment | 12 |
15 | 15 | M | T7–9 | Symmetry | / | ACV 800 mg × 5/d 7 days | 13 |
16 | 33 | F | Upper sacral areas, hips, and upper part of the buttocks bilaterally | Symmetry | / | ? | 14 |
17 | 24 | M | Chest | Symmetry | / | ? | 15 |
18 | 18 | M | Face and head | Symmetry | / | ? | 16 |
19 | 54 | M | Neck | Symmetry | / | ACV IV 21 days | 17 |
20 | 23 | M | Forehead and temporal areas | Symmetry | / | ? | 18 |
21 | 55 | M | T4 | Symmetry | / | ACV 800 mg × 5/d 7 days | 10 |
22 | 75 | M | Trigeminal nerve dermatome | Symmetry | Prostate carcinoma | ACV | 19 |
23 | 70 | M | R: C4, T2 L: L1–2 | Asymmetry | CLL | ACV IV 10 mg/kg/8 h | 20 |
24 | 70 | M | R: C4, T4 L: T9–10 | Asymmetry | Diabetic, CKD and MM | ACV 375 mg/d 10 days | 21 |
25 | 39 | F | T8 | Symmetry | After thoracoscopic splanchnicectomy | ACV oral 800 mg × 5/d 5 days | 22 |
26 | 31 | M | Eyes | Symmetry | AIDS | ACV oral 800 mg × 5/d | 23 |
27 | 66 | F | R: C4–5 L: facial and the posterior auricular nerves | Asymmetry | Rheumatism and heart disease | ? | 24 |
28 | 63 | M | T11 | Symmetry | ESRD | VCV oral 250 mg/d | 25 |
29 | 54 | F | R: T5–7 L: T10 | Asymmetry | MM | FCV | 26 |
30 | 52 | F | Face and neck | Symmetry | SLE, TB | ? | 27 |
31 | 21 | M | R: T9–10 L: T9 | Asymmetry | UC | Antiviral IV | 28 |
32 | 47 | F | L4–5, S1 | Symmetry | Renal transplantation | VCV oral 1 g tid 7 daysVCV oral 1 g/d 6 months | 29 |
33 | 27 | M | R: T9 L: T6–8 | Asymmetry | Pharyngotonsillitis | Oseltamivir oral | 30 |
34 | 49 | F | T4 | Symmetry | Breast cancer | FCV 700 mg/d 7 days | 31 |
35 | 68 | F | R: T8–9 L: C4 | Asymmetry | MM | ACV 750 mg/d 6 days | 32 |
36 | 30 | M | T10 | Symmetry | AIDS | ? | 33 |
37 | 64 | F | R: L4 L: T10 | Asymmetry | PAAS and diabetes | ACV 10 mg/kg tid | 34 |
38 | 67 | F | R: L4–5 L: T7–8 | Asymmetry | Hypertension | FCV 750 mg/d 7 days | 35 |
39 | 69 | M | R: T5–7,10,12; L3–4 L: T4–6,12; L3–5 | Asymmetry | ESRD and SCCs | ACV IV 800 mg/d 7 days FCV oral 500 mg/d 14 days | 36 |
40 | 91 | F | L2–5 | Symmetry | CKD | Antiviral therapy | 37 |